TORONTO, June 11 /CNW/ - Patheon Inc. (TSX: PTI) a global provider of
drug development and manufacturing services to the international
pharmaceutical industry, today announced it will expand the Manati, Puerto
Rico facility to add a dedicated high potency and controlled substance
manufacturing area. Patheon will invest a total of $2.8 million in this new
3,386ft(2) area that will include three manufacturing suites, air lock
containment areas, and humidity controlled air systems.
The three manufacturing suites will enable Patheon to combine in one
manufacturing area technology transfer, bulk production, bulk packaging, and
storage. The production area will have capacity for high potency (containment
down to 1 (micro)g/m(3) OEL) and humidity controlled solid dosage form
products. The construction project is currently in a fast track mode with
completion expected, based on current activity, by the end of September 2008.
Patheon has been contracted by one customer to utilize the suites and the
expansion will also provide substantial capacity to serve additional
"The Manati expansion is part of our strategy to satisfy the special
manufacturing needs of our current and future customers," stated Terry Novak,
President of North America and Chief Marketing Officer. "Other Patheon sites
have extensive capabilities to manufacture products of this type. The addition
of this capability in Puerto Rico provides another high quality manufacturing
site option to our customers."
Patheon Inc. (TSX:PTI; www.patheon.com) is a leading global provider of
contract development and manufacturing services to the global pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 270 of the world's leading pharmaceutical and
biotechnology companies. Patheon's services range from preclinical development
through commercial manufacturing of a full array of dosage forms including
parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative
technologies including single-use disposables, Liquid-Filled Hard Capsules and
a variety of modified release technologies.
Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon
can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(TM) programs can
accelerate early phase development project to clinical trials while minimizing
the consumption of valuable API.
Patheon's integrated development and manufacturing network of 12 sites,
with locations across North America and Europe, strives to ensure that
customer products can be launched with confidence anywhere in the world.
Caution Concerning Forward-Looking Statements
This news release may contain forward-looking statements which reflect
management's expectations regarding the Company's future growth of operations,
performance (both operational and financial) and business prospects and
opportunities. These statements are made in the context of the risks and
uncertainties that are outlined in the Company's public documents, which can
be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.
For further information:
For further information: Mr. Wes Wheeler, President & Chief Executive
Officer, Tel: (905) 812-2112, Email: email@example.com; Mr. Terry Novak,
President of North America, Chief Marketing Officer, Tel: (862) 207-1262,
Email: firstname.lastname@example.org; Ms. Jean Treadwell, Investor Relations, Tel:
(905) 816-8344, Email: email@example.com